Accueil   Diary - News   All news Poxel announces completion of patient enrollment

Poxel announces completion of patient enrollment

 

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that patient enrollment has been completed in the TIMES 3 trial of the Phase 3 registration program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 registration program in Japan includes three pivotal trials to evaluate the efficacy and safety of Imeglimin in approximately 1,100 patients. The TIMES 3 trial is a double-blind, placebo-controlled, randomized study with an open-label extension period to evaluate the efficacy and safety of Imeglimin in combination with insulin in over 200 Japanese patients with type 2 diabetes and inadequate glycemic control on insulin therapy.



Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree